Drug improves metastatic prostate cancer survival

​​​​​​​The first interim results of ENZAMET have been reported by an Australian-led team
Clare Pain
Model illustrating prostate cancer

Taking enzalutamide improves overall survival and progression-free survival in men with hormone-sensitive metastatic prostate cancer compared with standard antiandrogen therapies, report Australian researchers.

The first interim results of the ENZAMET trial show that men on enzalutamide are 33% less likely to have died than men on standard therapy after a median of 34 months’ follow-up.